A safety study of SGN-35C in adults with advanced cancers
Research type
Research Study
Full title
A phase 1, open-label study to evaluate SGN-35C in adults with advanced malignancies
IRAS ID
1009535
Contact name
Tara Chen
Contact email
Sponsor organisation
Seagen Inc.
Clinicaltrials.gov Identifier
Research summary
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).
This clinical trial uses a drug called SGN 35C. The study drug is in testing and has not been approved for sale. This is the first time SGN 35C will be used in people.
The study drug will be given as an infusion through a vein once every 3 weeks.
Subjects may keep getting SGN 35C as long as the study is open if
• their cancer stays the same or gets better,
• they don’t have bad side effects, and
• the study doctor agrees the subject should continue getting SGN 35C.
When subjects are getting SGN 35C, clinic visits will happen once every 3 weeks. After subjects stop getting the study drug, study staff will contact the subject about every 3 months. Subjects will continue to have scans every 3 months. Subjects will stop getting scans if their cancer gets worse, they get another cancer treatment, or it has been 2 years since their last dose of study drug.REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
24/NE/0088
Date of REC Opinion
21 Jun 2024
REC opinion
Further Information Favourable Opinion